Sternoclavicular Joint Tubercular Abscess in a Patient with Spondyloarthritis on Tofacitinib: A Case Report

B Sai Sunil, Prasanta Padhan, Debashis Maikap

Department of Clinical Immunology and Rheumatology, Kalinga Institute of Medical Sciences, KIIT University, Bhubaneswar, Odisha, India

Corresponding Author: Debashis Maikap MD, Assistant Professor, Department of Clinical Immunology and Rheumatology, Kalinga Institute of Medical Sciences, KIIT University, Bhubaneswar, 751024 Odisha, India; Tel.: +91 940 145 062, E-mail: debashmaikap29@gmail.com

Keywords: spondyloarthritis, tuberculosis, sternoclavicular joint

PRESENTATION
A 52-year-old male with axial spondyloarthritis presented to us with a painless swelling in the right sternoclavicular joint for one month. Over the past week, the patient reported an increase in the size of the swelling. He had no other symptoms such as fever or weight loss. The patient was taking tofacitinib for the last six months after ruling out latent tuberculosis with a negative Mantoux test and normal chest X-ray. Local examination revealed a 3x4 cm swelling in the region of the right sternoclavicular joint that was erythematous and tender (Figure 1A). The systemic clinical examination and laboratory workup were unremarkable except for raised C-reactive protein (CRP) levels of 32 mg/L (normal < 6 mg/L) and an Erythrocyte sedimentation rate (ESR) of 50 mm in the first hour. The interferon-gamma (IFN-γ) release assay (IGRA), test was positive. A chest radiograph (PA view) revealed normal lung parenchyma. A computerised tomography scan of the chest revealed lytic lesions with adjacent few tiny bone fragments and oedematous soft tissue planes were noted in the proximal end of the right clavicle (Figure 1B). An incision and drainage procedure was performed on the affected site. Gram stain and culture of the pus were negative for bacteria. However, the Ziehl-Neelsen stain was positive for acid-fast bacilli, and the blood culture showed no evidence of bacterial growth. Furthermore, the tuberculosis (TB) polymerase chain reaction (PCR) test confirmed the presence of Mycobacterium tuberculosis. The patient was registered under the national tuberculosis elimination programme (NTEP) and started on Anti-tubercular therapy. On follow-up at 6 months, the wound had healed. The patient received a full course of anti-tubercular therapy (ATT) for 12 months, comprising two months of HRZE followed by ten months of HRE.

DISCUSSION
Tuberculosis affecting bones and joints is rare, constituting only 1% to 3% of all tuberculosis cases.1 Sternum and sternoclavicular regions are affected in approximately 1% of musculoskeletal tuberculosis cases.1,2 Patients with sternoclavicular joint tuberculosis may experience painful swelling, painless swelling, or sinus, although the latter is rare.3 Janus kinase (JAK) inhibitors have recently been introduced in the management of spondyloarthritis, but their use increases the risk of TB infections. Tofacitinib is a JAK inhibitor, which preferentially inhibits JAK3 and JAK1, modulating the immune response via downregulation of several cytokines (eg, interleukins [ILs] 2, 4, 7, 9, 15 and 21) that are integral to lymphocyte development and function. It indirectly affects TNF by blocking interferons. It has been hypothesized that blockade of IL-12 or IL-23 (which act through JAK2/TYK2) might lead to inhibition of IFNy production by T cells.
Joint Tuberculosis due to Tofacitinib Use

TNFα is essential in granuloma formation while IFNγ is vital in preventing TB dissemination.

Before starting JAK inhibitors, it's important to screen for TB infection using both Interferon-gamma release assay (IGRA)/Quantiferon TB gold, and Mantoux tests as per an Egyptian study. Relying solely on the Mantoux test may miss cases of latent tuberculosis in TB-endemic areas like India.

A thorough evaluation of the potential risks and benefits, along with regular monitoring for TB infection, is crucial to ensure the safe and effective use of JAK inhibitors in clinical practice.

FUNDING
This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.

CONFLICT OF INTEREST
There was no conflict of interest among the authors.

INFORMED CONSENT
Written informed consent was obtained from the patient.

AUTHOR CONTRIBUTIONS
Concepts: BSS, PP, DM; Design: BSS, PP, DM; Definition of intellectual content: BSS, PP, DM; Literature search: BSS, DM; Data acquisition & analysis: BSS, DM; Manuscript preparation: BSS; Manuscript editing: PP, DM; Manuscript review: BSS, PP, DM.

REFERENCES